现代腋窝治疗对乳腺癌患者报告的手臂症状与躯体功能的影响
研究纳入UMBRELLA队列中接受局部放疗并伴前哨淋巴结活检、腋窝淋巴结清扫和/或腋窝放疗的949例乳腺癌患者,采用EORTC QLQ C30/BR23问卷随访至放疗开始后18个月。结果显示,腋窝淋巴结清扫联合腋窝放疗的手臂症状最重,腋窝放疗手臂症状少于腋窝淋巴结清扫,仅照射I-II站与I-IV站的手臂症状相似。
要点
- 仅前哨淋巴结活检的患者手臂症状评分最低,腋窝淋巴结清扫联合腋窝放疗者最高。
- 前3个月内,腋窝放疗(I-II站或I-IV站)的手臂症状显著少于腋窝淋巴结清扫。
- 仅照射I-II站与照射I-IV站的患者手臂症状评分相似,未带来有临床意义的降低。
核心结论
- 在所有腋窝处理策略中,腋窝淋巴结清扫联合腋窝放疗与最差的患者报告结局相关。
- 与腋窝淋巴结清扫相比,腋窝放疗的手臂症状更少。
- 选择性照射腋窝I-II站而非I-IV站,未带来有临床意义的手臂症状降低。
研究设计与样本
- 选取UMBRELLA队列中接受局部放疗并伴前哨淋巴结活检、腋窝淋巴结清扫和/或腋窝放疗的所有患者。
- 共识别949例患者:仅前哨淋巴结活检641例(68%),仅腋窝淋巴结清扫57例(6%),腋窝放疗I-II站94例(10%),腋窝放疗I-IV站72例(8%),腋窝淋巴结清扫联合腋窝放疗85例(9%)。
- 采用EORTC QLQ C30/BR23问卷评估患者报告的手臂症状与躯体功能,随访至放疗开始后18个月。
- 通过混合模型分析比较各组患者报告结局。
主要发现
- 仅前哨淋巴结活检组的手臂症状评分最低。
- 腋窝淋巴结清扫联合腋窝放疗组的手臂症状最多,在18个月时存在有临床意义的差异。
- 前3个月内,腋窝放疗(I-II站或I-IV站)的手臂症状显著少于腋窝淋巴结清扫。
- 接受腋窝放疗I-II站与I-IV站的患者手臂症状评分相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To reduce arm morbidity, routine axillary lymph node dissection (ALND) is often omitted or replaced by axillary radiotherapy (AxRT) in patients with limited nodal involvement. We evaluated patient-reported arm morbidity and physical functioning in breast cancer patients undergoing modern-day axillary treatment. METHODS: All patients within the UMBRELLA cohort undergoing local radiotherapy with sentinel lymph node biopsy (SLNB), ALND and/or AxRT were selected. Patient-reported arm morbidity and physical functioning were assessed with EORTC QLQ C30/BR23 questionnaires up to eighteen months after initiation of radiotherapy. Patient-reported outcomes were compared between patients with SLNB only, ALND only, AxRT (level I-II), AxRT (level I-IV) or AxRT plus ALND by means of mixed model analysis. RESULTS: In total, 949 patients were identified; 641 (68%) SLNB only, 57 (6%) ALND only, 94 (10%) AxRT level I-II, 72 (8%) AxRT level I-IV and 85 (9%) ALND + AxRT. SLNB only resulted in the least arm morbidity scores. ALND + AxRT resulted in most arm morbidity, with clinically relevant differences at 18 months. AxRT (level I-II or level I-IV) resulted in significantly less arm symptoms in the first 3 months compared to ALND. Arm symptom scores between those receiving AxRT on levels I-II and I-IV were similar. CONCLUSION: Of all axillary management strategies, ALND plus AxRT is associated with worst patient-reported outcomes. AxRT resulted in less arm morbidity compared to ALND. Selective radiotherapy treatment of the axilla, i.e. radiotherapy of levels I-II only instead of levels I-IV, did not lead to clinically relevant reduced arm morbidity.
引用
- Gregorowitsch ML, Verkooijen HM, Houweling A, et al. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Radiother Oncol. 2018. PMID: 30033384. doi:10.1016/j.radonc.2018.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。